AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
gepirone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anxiolytics, buspirone derivatives | 4562 | 83928-76-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Gepirone is indicated for the treatment of major depressive disorder in adults. The mechanism of its antidepressant effect is not fully understood but is thought to be related to its modulation of serotonergic activity in the CNS through selective agonist activity at 5HT1A receptors.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 15 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,MAP3K21,MAP3K7,MAPK7,NTRK2,PDK2,PIK3CB,PRKDC,SIK2,SIK3,STK33,TEK | 27 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,STK33,TEK | 5 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.451 | Moderate | 0.74 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.74 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.231 | % | Moderate | 0.74 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 22, 2023 | FDA | FABRE-KRAMER PHARMACEUTICALS, INC. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N06AX19 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| MeSH PA | D014151 | Anti-Anxiety Agents |
| MeSH PA | D017366 | Serotonin Receptor Agonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018490 | Serotonin Agents |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35941 | serotonergic agonist |
Related Drugs by ATC class:
N06AX Other antidepressants 28 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Major depressive disorder | indication | 370143000 | |
| Severe hepatic impairment | contraindication | 59927004 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Monoamine oxidase inhibitor | contraindication | 734595009 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.51 | Basic |
| pKa2 | 2.23 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 18.2MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | 7538116 | Sept. 2, 2030 | TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITH SEXUAL DYSFUNCTION CAUSED BY EITHER MAJOR DEPRESSION OR PRIOR TREATMENTS, OR TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITHOUT THE RISK OF SEXUAL DYSFUNCTION ADVERSE REACTIONS |
| EQ 36.3MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | 7538116 | Sept. 2, 2030 | TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITH SEXUAL DYSFUNCTION CAUSED BY EITHER MAJOR DEPRESSION OR PRIOR TREATMENTS, OR TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITHOUT THE RISK OF SEXUAL DYSFUNCTION ADVERSE REACTIONS |
| EQ 54.5MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | 7538116 | Sept. 2, 2030 | TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITH SEXUAL DYSFUNCTION CAUSED BY EITHER MAJOR DEPRESSION OR PRIOR TREATMENTS, OR TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITHOUT THE RISK OF SEXUAL DYSFUNCTION ADVERSE REACTIONS |
| EQ 72.6MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | 7538116 | Sept. 2, 2030 | TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITH SEXUAL DYSFUNCTION CAUSED BY EITHER MAJOR DEPRESSION OR PRIOR TREATMENTS, OR TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITHOUT THE RISK OF SEXUAL DYSFUNCTION ADVERSE REACTIONS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 18.2MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | Sept. 22, 2028 | NEW CHEMICAL ENTITY |
| EQ 36.3MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | Sept. 22, 2028 | NEW CHEMICAL ENTITY |
| EQ 54.5MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | Sept. 22, 2028 | NEW CHEMICAL ENTITY |
| EQ 72.6MG BASE | EXXUA | FABRE KRAMER | N021164 | Sept. 22, 2023 | RX | TABLET, EXTENDED RELEASE | ORAL | Sept. 22, 2028 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| D(2) dopamine receptor | GPCR | Ki | 7.24 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | AGONIST | Ki | 7.89 | CHEMBL | ||||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.44 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | Ki | 7.50 | CHEMBL | |||||
| Serotonin 1 (5-HT1) receptor | GPCR | IC50 | 6.17 | CHEMBL | |||||
| Adrenergic receptor alpha-1 | GPCR | Ki | 5.62 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4044261 | VANDF |
| CHEBI:135990 | CHEBI |
| CHEMBL284092 | ChEMBL_ID |
| C039979 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12930 | IUPHAR_LIGAND_ID |
| 5676 | INN_ID |
| DB12184 | DRUGBANK_ID |
| JW5Y7B8Z18 | UNII |
| 2672253 | RXNORM |
| 371477 | MMSL |
| 41993 | MMSL |
| d10111 | MMSL |
| 019595 | NDDF |
| 019596 | NDDF |
| C0066624 | UMLSCUI |
| A1ESA | PDB_CHEM_ID |
| CHEMBL1204187 | ChEMBL_ID |
| 55191 | PUBCHEM_CID |
| 83928-66-9 | SECONDARY_CAS_RN |
| JW5Y7B8Z18 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| EXXUA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-150 | TABLET, EXTENDED RELEASE | 18.20 mg | ORAL | NDA | 29 sections |
| EXXUA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-151 | TABLET, EXTENDED RELEASE | 36.30 mg | ORAL | NDA | 29 sections |
| EXXUA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-152 | TABLET, EXTENDED RELEASE | 54.50 mg | ORAL | NDA | 29 sections |
| EXXUA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23594-153 | TABLET, EXTENDED RELEASE | 72.60 mg | ORAL | NDA | 29 sections |